Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Chonluten Dosing Protocol: 20 mg Vial — Lung & Bronchial Bioregulator Guide

Chonluten (Glu-Asp-Leu tripeptide) Russian lung bioregulator dosing guide — bronchial epithelial cell gene normalization for respiratory function and lung aging support.

Quickstart highlights

Chonluten (Glu-Asp-Leu) is a synthetic tripeptide bioregulator developed by Khavinson targeting bronchial epithelial cells and alveolar pneumocytes.

  • Concentration: 2 mg/mL (20 mg vial + 10 mL bac water, in 2.5 mL portions).
  • At 2 mg/mL: 200 µg = 10 units once daily x 10 days.
  • Chonluten targets bronchial epithelial cell gene expression normalization.
  • Russian application: COPD, asthma, post-COVID lung recovery, age-related decline.
  • One 20 mg vial: 100 doses — 10 complete 10-day courses.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-2 (10-day course)20010Once daily200 µg — 10 units; 10-day intensive course; 20 mg vial = 100 doses
Maintenance20010Every other day200 µg EOD — chronic lung health support

Reconstitution steps

  1. Reconstitute in 2.5 mL bac water portions (5 mg per batch); inject slowly down vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 2 mg/mL. At 2 mg/mL: 200 µg = 10 units.
  4. Label with date; refrigerate 2–8 °C. Use within 28 days.

Supplies needed

10_day-week plan

  • 1 vial
  • 10 syringes
  • 2 mL bac water
  • 10 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Normalize bronchial epithelial and alveolar cell gene expression through the Chonluten tripeptide lung bioregulator, supporting respiratory function recovery and lung aging resistance.

Off-cycle: 4–6 months between 10-day intensive courses.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted: refrigerate 2–8 °C; use within 28 days.

Injection & tracking tips

  • Inject subcutaneously at any time of day — no specific timing advantage for pulmonary bioregulators.
  • Chonluten is used in Russian clinical settings for COPD, asthma, post-COVID lung recovery, and age-related respiratory decline.
  • Inhalation route has been explored but SC injection is standard for compounding protocols.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure FEV1 and FVC (spirometry) at baseline and 3 months post-course.
  • Track 6-minute walk distance weekly for functional capacity.
  • Log daily dyspnea score (Borg scale 0–10) and morning peak expiratory flow rate.
Log your cycle in the calculator →

How this works & references

Chonluten (Glu-Asp-Leu) is a synthetic tripeptide bioregulator developed by Khavinson targeting bronchial epithelial cells and alveolar pneumocytes. Russian bioregulator research posits that short organ-specific peptides penetrate target tissue cells and interact directly with chromatin, normalizing gene expression patterns disrupted by aging, pollution, infection, or chronic inflammation. Chonluten has been applied in Russian clinical settings for COPD support, post-infectious lung recovery, and age-related pulmonary function decline. Published evidence is predominantly in Russian medical journals.

Sources

Frequently asked questions

Can Chonluten help with post-COVID lung damage?
Russian practitioners have applied Chonluten in post-COVID lung recovery protocols, targeting persistent alveolar inflammation and fibrotic remodeling. The mechanism (normalizing bronchial epithelial gene expression, reducing pro-inflammatory cytokine transcription) is consistent with the pathology. No RCT in post-COVID populations exists; the application is extrapolated from COPD and pulmonary aging data.
What is a tripeptide bioregulator versus a tetrapeptide?
Both are Khavinson peptide bioregulators; length varies: Vilon is a dipeptide (2 AA), Chonluten is a tripeptide (3 AA), Cardiogen/Epithalon are tetrapeptides (4 AA). Length affects tissue penetration and receptor interaction specificity. Shorter peptides penetrate tissues more readily but may have broader (less organ-specific) activity.
Is there evidence Chonluten helps smokers?
No RCT in current smokers. Russian bioregulator protocols discourage use in active smokers due to ongoing epithelial damage that may overwhelm bioregulator repair capacity. For former smokers with residual COPD or FEV1 decline, Chonluten may normalize the remaining epithelial gene expression and slow further decline.
Can Chonluten be combined with Thymosin Alpha-1?
Yes — Thymosin Alpha-1 (immune activation and antiviral defense) + Chonluten (bronchial epithelial gene normalization) is a logical combination for post-infectious or post-COVID respiratory impairment. They act through complementary pathways. Use sequentially (separate 10-day courses) rather than simultaneously for cleaner dose tracking.
Is there any risk of Chonluten worsening asthma?
No documented adverse effects in asthmatic patients from Russian clinical experience. The gene normalization mechanism would theoretically reduce (not increase) inflammatory signaling. However, given the absence of RCT data, asthmatic patients should monitor FEV1 and peak flow closely during the first 10-day course.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.